The National Retail Federation on Wednesday launched a 60-day lobbying, grassroots and media campaign aimed at ensuring that a new federal law — which is designed to save retailers and their customers more than $1 billion a month by lowering the “swipe fees" banks charge to process debit card transactions — takes effect in late July as scheduled.
The Generic Pharmaceutical Association and other trade and patient advocacy groups can push generic drug usage as a way to save on medical costs, but throwing the weight of Congress behind generics gives them a bigger boost than ever.
ORLANDO, Fla. — Studies have indicated that the best people to get patients to adhere to their medication therapies are store pharmacists, while the second-best people are nurses. Thus, it’s only natural that getting nurses and pharmacists to collaborate will further improve adherence. The collaborative care track that The Drug Store News Group will introduce at the Retail Clinician Education Congress in August is a step in that direction.
Local pharmacists work with patients and law enforcement to combat the abuse of controlled substances and other prescription drugs, but changes to federal policy are needed to allow pharmacists to play a greater role, the National Community Pharmacists Association suggested Thursday in comments submitted to Congress.
Just two weeks after expressing its discouragement caused by the delayed swipe-fee reform, the National Retail Federation lauded a letter from a coalition of consumer groups that also opposed the delay, which is slated to go into effect this summer.
Studies have indicated that the best people to get patients to adhere to their medication therapies are store pharmacists, while the second-best people are nurses. Thus, it’s only natural that getting nurses and pharmacists to collaborate will further improve adherence. The collaborative care track that The Drug Store News Group will introduce at the Retail Clinician Education Congress in August is a step in that direction.
The generic drug industry’s main lobby in Washington is hoping to head off cuts to the Food and Drug Administration’s Office of Generic Drugs, which it said could have a “devastating impact” on those who rely on generics.
It's about time lawmakers start to understand the real threats posed by drug reimportation and unlicensed Internet pharmacy sites. About 20% of the current members of Congress are newly elected, and there is this recurring, cyclical fascination among politicians that we can fix everything with drug reimportation. But mandating electronic track and trace right now is a bad idea.
The National Retail Federation said legislation introduced Tuesday to delay swipe fee reform, which is scheduled to go into effect this summer, would block retailers from giving discounts to consumers who use debit cards and would cost merchants and the public more than $1 billion per month.
Ten members of Congress expressed concerns over a provision in the Patient Protection and Affordable Care Act that is said to reduce Medicare program costs, according to the Centers for Medicare and Medicaid Services.
The National Association of Chain Drug Stores and the National Community Pharmacists Association on Tuesday urged Congress to permit the Federal Reserve Board to expedite the implementation of an amendment to the financial-reform legislation.
Capitol Hill will turn into a sea of white lab coats Wednesday and Thursday as more than 350 pharmacy advocates from almost 40 states visit Washington for the third annual National Association of Chain Drug Stores RxImpact Day, NACDS said Wednesday.
Walgreens’ winning of an award for its MTM services came right before it joined the Care Continuum Alliance — a group of more than 200 stakeholders that provide such services as wellness and prevention programs and management of chronic conditions — of which CVS Caremark already was a member.
As one retail pharmacy executive put it, "many members of Congress only experience the pharmacy industry through their eyes as a patient." Thanks to NACDS RxImpact Day on Capitol Hill, however, that no longer has to be the case.
Though efforts to repeal the Patient Protection and Affordable Care Act via the court system remain under way — with recent victories for opponents in Virginia and Florida — the attempt to repeal the healthcare-reform bill in Congress failed, thus leaving the bill and, most importantly, the regulatory approval pathway for follow-on biologics intact.
The National Association of Chain Drug Stores and its members from across the country once again are flocking to Capitol Hill for RxImpact Day, a groundbreaking, two-day event that enables pharmacists to meet with members of Congress to discuss the vital role of retail pharmacy within the U.S. healthcare system and its ability to help reduce annual healthcare costs.
It never made much sense to make health care less affordable under the Affordable Care Act — neither did the requirement of a prescription for a nonprescription remedy jive with proponents of flexible spending accounts. So it’s little wonder that the FSA rule changes were the first piece of ObamaCare to face a congressional axe, as was widely speculated just last week.
As soon as members of Congress took their seats last month, the new Republican majority announced it would make good on its pledge to repeal the Patient Protection and Affordable Care Act. The effort largely is symbolic and unlikely to succeed, so at least one portion of the healthcare-reform law will likely remain in effect, namely the abbreviated approval pathway for follow-on biologics, also known as the Biologics Price Competition and Innovation Act.